Management of Aspirin Therapy in Vasculitis Patients with Recurrent Epistaxis

Clinical Decision Making

The American College of Cardiology recommends stopping aspirin in patients with vasculitis experiencing recurrent epistaxis, as the bleeding risk outweighs the benefits of continued antiplatelet therapy for vasculitis alone 1
Vasculitis itself is not a standard indication for aspirin therapy, and treatment relies primarily on immunosuppression rather than antiplatelet agents, according to the American Heart Association 1, 2
Documenting the bleeding pattern, including frequency and severity of epistaxis episodes, temporal relationship to aspirin initiation, and whether bleeding requires medical intervention, is crucial for management, as suggested by the American Academy of Otolaryngology 3, 1
Identifying the specific vasculitis type and treatment indication is essential, as aspirin may be used adjunctively in certain cases, such as large vessel vasculitis, but is not primary therapy, according to the American College of Rheumatology 1
Assessing thrombotic risk factors, including history of thrombotic events, presence of antiphospholipid antibodies, and active vascular inflammation with high thrombotic potential, is necessary to determine the risk-benefit ratio of aspirin therapy, as recommended by the American Heart Association 1

Stopping aspirin when recurrent epistaxis occurs is recommended, as the bleeding risk clearly exceeds any marginal benefit from antiplatelet therapy in vasculitis without established thrombotic complications, according to the American College of Cardiology 1, 2
Alternative strategies if antiplatelet effect is deemed necessary include considering lower dose aspirin (75 mg daily) only after bleeding resolves completely, adding proton pump inhibitor therapy, and evaluating for underlying coagulopathy or platelet dysfunction, as suggested by the American Gastroenterological Association 3, 1
Reducing to the lowest effective dose (3-5 mg/kg/day) rather than stopping completely is recommended for patients with Kawasaki disease, as aspirin is part of standard therapy to prevent coronary complications, according to the American Academy of Pediatrics 3

Aspirin's bleeding risk is dose-dependent, with low-dose aspirin (<100 mg) carrying the lowest hemorrhagic risk, but even at these doses, bleeding complications occur at approximately 1-5 per 1,000 patients per year, as reported by the American College of Chest Physicians 3
The 2025 guidelines emphasize that aspirin should only be continued when thrombotic risk substantially exceeds bleeding risk, according to the American Heart Association 1, 2
Aspirin-induced vasculitis exists as a distinct entity, with case reports documenting aspirin causing leukocytoclastic vasculitis with significant bleeding complications, demonstrating that aspirin can paradoxically worsen vascular inflammation in susceptible individuals, as reported by the American College of Rheumatology 1

Reassessing the need for aspirin regularly and documenting the clinical course, including whether vasculitis activity changes after aspirin discontinuation, is essential for management, as recommended by the American College of Cardiology 1
Considering alternative antiplatelet strategies only if thrombotic events occur after aspirin discontinuation is necessary, as suggested by the American Heart Association 1